CA2351224A1 - Utilisation d'une combinaison d'inhibiteurs de cox-2 et de substances bloquant les recepteurs de nmda pour le traitement de la douleur - Google Patents

Utilisation d'une combinaison d'inhibiteurs de cox-2 et de substances bloquant les recepteurs de nmda pour le traitement de la douleur Download PDF

Info

Publication number
CA2351224A1
CA2351224A1 CA002351224A CA2351224A CA2351224A1 CA 2351224 A1 CA2351224 A1 CA 2351224A1 CA 002351224 A CA002351224 A CA 002351224A CA 2351224 A CA2351224 A CA 2351224A CA 2351224 A1 CA2351224 A1 CA 2351224A1
Authority
CA
Canada
Prior art keywords
phenyl
methylsulfonyl
fluorophenyl
group
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002351224A
Other languages
English (en)
Inventor
Frank S. Caruso
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endo Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2351224A1 publication Critical patent/CA2351224A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention se rapporte à une méthode visant à soulager un état douloreux qui n'est pas accompagné de toux, et consistant à administrer à un mammifère présentant un état de douleur non accompagné de toux un inhibiteur de cyclooxygénase-2 ainsi qu'un antagoniste non toxique des récepteurs de NMDA et/ou une substance non toxique qui supprime au moins une des conséquences intracellulaires majeures de l'activation des récepteurs de NMDA.
CA002351224A 1998-11-12 1998-11-12 Utilisation d'une combinaison d'inhibiteurs de cox-2 et de substances bloquant les recepteurs de nmda pour le traitement de la douleur Abandoned CA2351224A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1998/024317 WO2000029023A1 (fr) 1998-11-12 1998-11-12 Utilisation d'une combinaison d'inhibiteurs de cox-2 et de substances bloquant les recepteurs de nmda pour le traitement de la douleur

Publications (1)

Publication Number Publication Date
CA2351224A1 true CA2351224A1 (fr) 2000-05-25

Family

ID=22268299

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002351224A Abandoned CA2351224A1 (fr) 1998-11-12 1998-11-12 Utilisation d'une combinaison d'inhibiteurs de cox-2 et de substances bloquant les recepteurs de nmda pour le traitement de la douleur

Country Status (5)

Country Link
EP (1) EP1146905A1 (fr)
JP (1) JP2002538078A (fr)
AU (1) AU1408699A (fr)
CA (1) CA2351224A1 (fr)
WO (1) WO2000029023A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10059020A1 (de) 2000-11-28 2002-05-29 Gruenenthal Gmbh Parenteral applizierbare Darreichungsformen
EP1395289B1 (fr) 2001-06-07 2010-12-15 Christine Dr. Sang Traitement de la douleur nevropathique avec des antagonistes du recepteur n-methyl-d-aspartate (nmda)
US20040082543A1 (en) * 2002-10-29 2004-04-29 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
AU2004237439B2 (en) 2003-05-07 2009-09-10 Osteologix A/S Treating cartilage/bone conditions with water-soluble strontium salts
DK1648867T3 (da) * 2003-07-17 2013-12-16 Plexxikon Inc Ppar-aktive forbindelser
US20060002999A1 (en) 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
WO2006024018A2 (fr) * 2004-08-24 2006-03-02 Neuromolecular Pharmaceuticals, Inc. Methodes et compositions pour le traitement de la douleur nociceptive
WO2008055945A1 (fr) 2006-11-09 2008-05-15 Probiodrug Ag Dérivés 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one utiles en tant qu' inhibiteurs de la glutaminyl-cyclase dans le traitement des ulcères, du cancer et d'autres maladies
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
CN101668525A (zh) 2007-03-01 2010-03-10 前体生物药物股份公司 谷氨酰胺酰环化酶抑制剂的新用途
EP2142514B1 (fr) 2007-04-18 2014-12-24 Probiodrug AG Dérivés de thio-urée utilisés comme inhibiteurs de la glutaminyl cyclase
SG178953A1 (en) 2009-09-11 2012-04-27 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
DK2545047T3 (da) 2010-03-10 2014-07-28 Probiodrug Ag Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5)
WO2011131748A2 (fr) 2010-04-21 2011-10-27 Probiodrug Ag Nouveaux inhibiteurs
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
US20130274282A1 (en) * 2012-04-16 2013-10-17 Herriot Tabuteau Compositions and methods comprising celecoxib or related compounds and dextromethorphan
CA2919892C (fr) 2013-08-12 2019-06-18 Pharmaceutical Manufacturing Research Services, Inc. Comprime extrude anti-abus a liberation immediate
WO2015095391A1 (fr) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Comprimé extrudé anti-abus à libération prolongée
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9707184B2 (en) 2014-07-17 2017-07-18 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
EP3209282A4 (fr) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Forme galénique anti-abus de remplissage de liquide à libération prolongée
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5409944A (en) * 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
US5521213A (en) * 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
ES2211916T3 (es) * 1994-09-02 2004-07-16 Virginia Commonwealth University Composicion para aliviar dolor, que contiene un analgesico no narcortico y un potenciador de analgesia.
AU7472798A (en) * 1997-05-07 1998-11-27 Algos Pharmaceutical Corporation Cox-2 inhibitors in combination with nmda-blockers for treating pain
FR2771005B1 (fr) * 1997-11-18 2002-06-07 Union Pharma Scient Appl Nouvelle association pharmaceutique a activite analgesique

Also Published As

Publication number Publication date
EP1146905A1 (fr) 2001-10-24
WO2000029023A1 (fr) 2000-05-25
JP2002538078A (ja) 2002-11-12
AU1408699A (en) 2000-06-05

Similar Documents

Publication Publication Date Title
CA2351224A1 (fr) Utilisation d'une combinaison d'inhibiteurs de cox-2 et de substances bloquant les recepteurs de nmda pour le traitement de la douleur
WO1998050075A1 (fr) Inhibiteurs de cox-2 en combinaison avec des agents bloquants le nmda pour traiter la douleur
CA2345641A1 (fr) Procede de traitement de maladies inflammatoires par administration d'un inhibiteur de la thrombine
US20030220374A1 (en) Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
KR20010006443A (ko) 심장혈관 질환 예방에의 시클로 옥시게나제-2 억제제 사용방법
US20030212138A1 (en) Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
US20040204472A1 (en) Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents
EP1283723A2 (fr) Polytherapie faisant appel a un inhibiteur selectif de cox-2 et a un inhibiteur de la thromboxane ainsi que des compositions contenant ceux-ci
WO2000029022A1 (fr) Combinaison d'inhibiteurs de cox-2 et d'analgesiques a action centrale
AU753657B2 (en) Combination therapy for reducing the risks associated with cardio-and cerebrovascular disease
JP2005501850A (ja) シクロオキシゲナーゼ−２選択的阻害薬およびコンドロイチン硫酸を含む、疼痛および炎症を治療および予防するための組成物
US20020035156A1 (en) Combination therapy in the prevention of cardiovascular disorders
US20030207846A1 (en) Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
US20070072861A1 (en) Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders
PL206268B1 (pl) Kompozycja przeciwbólowa i/lub przeciwzapalna oraz jej zastosowanie
AU2001268377A1 (en) Analgesic and anti-inflammatory compositions containing COX-2 inhibitors
WO2005049014A1 (fr) Methodes de traitement ou de prevention de troubles oculaires lies au diabete par des inhibiteurs cox-2 seuls ou en association avec des agents anti-diabete classiques

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20041112